鉄欠乏性貧血治療市場の2028年までの予測- 治療法別、治療領域別、年齢別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、鉄欠乏性貧血（IDA）治療の世界市場は、2022年に18億7,000万米ドルを占め、2028年には23億6,000万米ドルに達すると予測され、予測期間中に3.95％のCAGRで成長するとされています。

鉄欠乏性貧血（IDA）は、血液中の健康な赤血球が十分でない場合に起こる症状です。赤血球は、血液中の酸素の貯蔵と輸送を助けるもので、鉄を使って作られます。赤血球は、人間の組織に酸素を供給します。赤血球には、ヘモグロビンの合成に必要な鉄分が含まれています。ヘモグロビンの量が不足していると、体に十分な酸素が供給されていないことが考えられます。果物、肉、野菜、穀物など、鉄分を多く含む食品は、治療や予防に役立てることができます。ビタミンCを摂取することで、鉄分不足を予防することができます。

2021年11月に発表された「Global Nutrition Report」によると、15～49歳のインド人女性の半数以上、つまり人口の約53％が貧血であることが判明しています。

市場力学：

促進要因

鉄欠乏性貧血の有病率の増加

鉄欠乏性貧血（IDA）は、世界の健康問題です。鉄欠乏性貧血は、様々な年齢層や性的指向の人々を巻き込んでいます。しかし、10代の女性はより影響を受けやすいと言われています。鉄の必要量の増加、毎月の出血、病気、虫の侵入が原因かもしれません。肉類など鉄分を多く含む食品を摂取しない人は、鉄欠乏性貧血になりやすいと考えられます。頻繁な献血や栄養不足が、鉄欠乏性貧血（IDA）治療薬の需要を高めています。

抑制要因

十分な検査の欠如

貧血は、さまざまな健康上の問題から発症する可能性があります。この状態を診断するための十分な検査がありません。貧血は適切に評価も治療もされない傾向にあります。一般的には鉄剤で管理され、単独の診断名として記録されます。その症状や指標の頻度や重症度は異なります。適切に管理されないと、心不全や死に至ることもあります。これらの要素が市場の需要を妨げています。

機会

がんの発生率の増加

がん患者は、鉄欠乏性貧血になる可能性が高くなっています。肺腫瘍と乳腺腫瘍は、固形腫瘍の中で最も貧血の頻度が高いことが示されています。貧血は、多発性骨髄腫、白血病、リンパ腫などの血液がんが作り出す異常な血球によって引き起こされます。これらの病気によって免疫力は低下しています。また、化学療法や放射線療法などのガン治療は、がん患者の貧血を悪化させます。このような側面から、市場にはさらなる可能性が広がっています。

脅威です：

鉄分サプリメントの副作用

鉄分を含む薬剤を摂取すると、吐き気、嘔吐、胃痛、便秘、食欲不振などの悪影響があります。また、これらの薬は、疲労、脱力、浅い呼吸や速い呼吸、青い肌、痙攣、青白い肌、青白い爪などの過剰摂取の症状を引き起こす可能性があります。これらの悪影響はすべて、市場の拡大を妨げています。

COVID-19の影響：

COVID-19のパンデミックはヘルスケアシステムに多大な影響を与え、COVID-19感染者と非感染者の双方に深刻な影響を及ぼし、治療の中止や資源の管理・確保のための手続きなどにつながっています。COVID-19患者における貧血の流行は、鉄剤治療やその他の貧血関連治療の必要性を高める結果となりました。

予測期間中、小児用セグメントが最大となる見込み

小児部門は有利な成長を遂げると推定されます。小児は鉄分不足に悩まされることが多いです。鉄分不足は、軽度のものから鉄欠乏性貧血まで、いくつかの形態があります。子供の成長と発達は、未治療の鉄欠乏症によって影響を受けるかもしれません。子どもの鉄分不足は、通常、栄養不足、発育の早さ、低出生体重児が原因です。ヘモグロビンとヘマトクリットの診断結果の向上が、この分野の需要を促進しています。

予測期間中、経口鉄剤のCAGRが最も高くなると予想されます。

経口鉄剤は、その高い鉄バランス回復能力により、予測期間中に最も速いCAGRの成長が見込まれます。鉄の貯蔵量を補充し、フェリチンレベルを正常化するためには、経口鉄剤を少なくとも3～6ヵ月間使用する必要があります。体内の鉄分とヘモグロビン濃度を上げることで、患者の症状を緩和させるのです。経口鉄剤には、さまざまなレベルの元素鉄が含まれています。

最もシェアの高い地域

北米は、ヘルスケアシステムが発達しているため、予測期間中に最大の市場シェアを占めると予測されています。同地域は医療インフラが整備されており、競合他社が少ないことから、鉄欠乏性貧血治療薬の需要が高まっています。また、女性の健康問題に対する消費者の意識の高まりや技術の向上が、この地域の市場拡大を後押ししています。

CAGRが最も高い地域：

アジア太平洋は、人口の増加と政府の取り組みにより、予測期間中に最も高いCAGRを示すと予測されます。この地域は、女性の人口が非常に多いです。この地域の市場需要は、ヘルスケアコストの上昇、ヘルスケアセクターを支援する政府の取り組み、IDA治療に対する需要の高まりによって牽引されています。

主な発展：

2023年2月、Rockwell Medical, Inc.は、米国の熟練看護施設における透析の最大手であるConcerto Renal Services（以下「Concerto」）と3年間の製品購入契約を締結したと発表しました。本契約により、ロックウェル・メディカルは、供給および購買の最低条件を含む3年間のコミットメントを通じて、液体および乾燥の酸および重炭酸濃縮液の主要サプライヤーとしてコンチェルト社に供給することになります。

2022年9月、Alkem Laboratoriesは、既製品の細胞治療製品であるStemOneが、インドでの発売についてインド医薬品監督庁（DCGI）から薬事承認を取得したと発表しました。Alkem LaboratoriesがStempeuticsと共同で発売した本製品は、関節の変性疾患である「膝の変形性関節症」の治療薬として使用されます。

2022年3月、Teva Pharmaceutical Industries Ltd.の米国関連会社であるTeva Pharmaceuticalsは、Revlimid（R）1（lenalidomide capsules）の初の後発品として、5mg、10mg、15mg、25mgの強度で、米国での発売を発表しました。

本レポートの内容

• 地域別および国別セグメントの市場シェア評価
• 新規参入企業への戦略的提言
• 2020年、2021年、2022年、2025年、2028年の市場データを網羅
• 市場促進要因（市場動向、制約要因、機会、脅威、課題、投資機会、推奨事項）。
• 市場推定に基づく、主要ビジネスセグメントにおける戦略的提言
• 主要な共通トレンドをマッピングした競合情勢。
• 詳細な戦略、財務、最近の開発状況を含む企業プロファイル
• 最新の技術的進歩をマッピングしたサプライチェーン動向

無料のカスタマイズ提供：

本レポートをご購入いただいたお客様には、以下の無料カスタマイズオプションのいずれかを提供させていただきます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的なプロファイリング（最大3社まで）
  • 主要プレイヤーのSWOT分析（3社まで）
• 地域別セグメンテーション
  • お客様のご希望に応じて、主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる。）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地域的プレゼンス、戦略的提携に基づく主要プレイヤーのベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 仮定

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の鉄欠乏性貧血（IDA）治療市場：治療法別

• 非経口鉄療法
• 経口鉄療法
• 赤血球輸血療法
• その他の治療法

第6章 世界の鉄欠乏性貧血（IDA）治療市場：治療領域別

• うっ血性心不全（CHF）
• 腎臓、産婦人科、
• 腫瘍学
• 炎症性腸疾患
• その他の治療分野

第7章 世界の鉄欠乏性貧血（IDA）治療市場：年齢別

• 高齢者向け
• 大人
• 小児

第8章 世界の鉄欠乏性貧血（IDA）治療市場：エンドユーザー別

• クリニック
• 病院
• 在宅ヘルスケア

第9章 世界の鉄欠乏性貧血（IDA）治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 会社概要

• Vifor Pharma Ltd
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Pfizer Inc
• Novartis AG
• Mylan N.V.
• Lupin
• Zydus Cadila
• GlaxoSmithKline plc
• Fresenius SE & Co. KGaA
• F. Hoffmann-La Roche Ltd
• Shield Therapeutics
• Pharmacosmos A/S
• AMAG Pharmaceuticals
• Akebia Therapeutics, Inc
• AbbVie Inc.
• Hikma Pharmaceuticals plc
• Alkem Laboratiories
• Advanz Pharmaceutical
• Rockwell Medical, Inc

List of Tables

• Table 1 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 3 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 4 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 5 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 6 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 7 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 8 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 9 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 10 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 11 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 12 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 13 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 14 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 15 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 16 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 17 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 18 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 19 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 20 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
• Table 21 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
• Table 22 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 23 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 24 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 25 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 26 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 27 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 28 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 29 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 30 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 31 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 32 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 33 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 34 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 35 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 36 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 37 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 38 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 39 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 40 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
• Table 41 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
• Table 42 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 43 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 44 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 45 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 46 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 47 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 48 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 49 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 50 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 51 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 52 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 53 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 54 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 55 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 56 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 57 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 58 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 59 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 60 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
• Table 61 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
• Table 62 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 63 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 64 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 65 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 66 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 67 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 68 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 69 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 70 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 71 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 72 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 73 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 74 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 75 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 76 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 77 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 78 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 79 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 80 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
• Table 81 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
• Table 82 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 83 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 84 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 85 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 86 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 87 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 88 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 89 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 90 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 91 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 92 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 93 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 94 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 95 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 96 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 97 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 98 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 99 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 100 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
• Table 101 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
• Table 102 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
• Table 103 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
• Table 104 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
• Table 105 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
• Table 106 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
• Table 107 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
• Table 108 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
• Table 109 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
• Table 110 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
• Table 111 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
• Table 112 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
• Table 113 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
• Table 114 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
• Table 115 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
• Table 116 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
• Table 117 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
• Table 118 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
• Table 119 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
• Table 120 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)

According to Stratistics MRC, the Global Iron Deficiency Anemia (IDA) Therapy Market is accounted for $1.87 billion in 2022 and is expected to reach $2.36 billion by 2028 growing at a CAGR of 3.95% during the forecast period. Iron Deficiency Anemia (IDA) is a condition that occurs when there are not enough healthy red blood cells in the blood. Red blood cells, which aid in storing and transporting oxygen in the blood, are created using iron. RBCs provide oxygen to human tissues. Red blood cells contain iron, which is necessary for haemoglobin synthesis. An inadequate amount of haemoglobin may indicate that the body is not receiving enough oxygen. Foods rich in iron, such as fruits, meat, vegetables, and cereals, can be used to treat or prevent it. Consuming vitamin C can help prevent iron shortage.

According to the Global Nutrition Report, published in November 2021, it has been found that over half of Indian women aged between 15 - 49 years that is about 53% of the population are anemic.

Market Dynamics:

Driver:

Increased prevalence of iron deficiency anaemia

Iron Deficiency Anaemia (IDA) is a global health problem. It involves people of various ages and sexual orientations. However, teenage females are more susceptible to it. Increased iron need, monthly blood loss, illness, and worm infestation might be the causes. People who don't consume meat or other foods high in iron may be more susceptible to iron deficiency anaemia. Frequent blood donations and nutritional deficiencies are raising the demand for Iron Deficiency Anaemia (IDA) Therapies.

Restraint:

Lack of adequate testing

Anaemia may develop from a variety of different health issues. There aren't enough tests available to diagnose this condition. Anaemia tends to be neither properly assessed nor treated. It is commonly managed with iron supplements and recorded as a standalone diagnosis. The frequency and severity of its symptoms and indicators differ. It can cause heart failure or death if not adequately managed. These elements hinder the market demand.

Opportunity:

Growing incidence of cancer

Cancer patients are becoming more likely to have iron deficient anaemia. Lung and breast tumours have been shown to have the greatest anaemic frequency among solid tumours. Anaemia is caused by the aberrant blood cells that hematologic cancers like multiple myeloma, leukaemia, and lymphoma create. The immune system is weakened by these illnesses. Cancer treatments like chemotherapy and radiation worsen anaemia in cancer patients. These aspects create more prospects to the market.

Threat:

Side effects of iron supplements

Consuming iron-containing medications causes negative effects such as nausea, vomiting, stomach aches and constipation and issues with appetite. These medications can also cause overdose symptoms such fatigue, weakness, shallow or rapid breathing, blue skin, convulsions, pale skin, or pale fingernails. All of these adverse impacts are hampering the market expansion.

COVID-19 Impact:

The COVID-19 pandemic had a tremendous influence on the healthcare systems, with serious ramifications for both COVID-19-infected patients and non-infected patients, leading to the cancellation of treatment and procedures to manage and reserve resources. The prevalence of anaemia in COVID-19 patients resulted in a rise in the need for iron therapy and other anaemia-related treatments.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Children frequently struggle with an iron shortage. It can take several forms, ranging from a minor deficit to iron deficiency anaemia. A child's growth and development might be impacted by untreated iron deficiency. Children's iron deficiencies are usually caused by inadequate nutrition, fast development, and low birth weight. Raising diagnosis of haemoglobin and hematocrit are driving the segment's demand.

The oral iron therapy segment is expected to have the highest CAGR during the forecast period

The oral iron therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its high iron balance restoring capacity. To replenish iron reserves and normalise ferritin levels, oral iron treatment must be used for at least three to six months. By raising the body's iron and haemoglobin levels, it alleviates the patient's symptoms. Different levels of elemental iron are included in oral iron supplements.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its developed healthcare system. The demand for iron deficiency anaemia treatments is increasing due to the region's developed healthcare infrastructure and the presence of significant market competitors. Additionally, expanding consumer awareness of women's health issues and technical improvements are propelling market expansion in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the increasing population and government initiatives. This region has huge population of women. The market demand in this area is being driven by rising healthcare costs, government initiatives to support the healthcare sector, and growing demand for IDA treatment.

Key players in the market:

Some of the key players profiled in the Iron Deficiency Anemia (IDA) Therapy Market include: Vifor Pharma Ltd, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Mylan N.V., Lupin, Zydus Cadila, GlaxoSmithKline plc, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Shield Therapeutics, Pharmacosmos A/S, AMAG Pharmaceuticals, Akebia Therapeutics, Inc, AbbVie Inc., Hikma Pharmaceuticals plc, Alkem Laboratiories, Advanz Pharmaceutical and Rockwell Medical, Inc.

Key Developments:

In February 2023, Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums.

In September 2022, Alkem Laboratories announced that its off-the-shelf cell therapy product, StemOne has received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. The product, launched by Alkem Laboratories in collaboration with Stempeutics, is for the treatment of Knee Osteoarthritis, a degenerative disease of the joint.

In March 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

Therapies Covered:

• Parenteral Iron Therapy
• Oral Iron Therapy
• Red Blood Cell Transfusion Therapy
• Other Therapies

Therapy Areas Covered:

• Congestive Heart Failure (CHF)
• Renal, Obstetrics & Gynaecology
• Oncology
• Inflammatory Bowel Disease
• Other Therapy Areas

Age Covered:

• Geriatric
• Adults
• Pediatric

End Users Covered:

• Clinics
• Hospitals
• Home Healthcare

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy

• 5.1 Introduction
• 5.2 Parenteral Iron Therapy
• 5.3 Oral Iron Therapy
• 5.4 Red Blood Cell Transfusion Therapy
• 5.5 Other Therapies

6 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy Area

• 6.1 Introduction
• 6.2 Congestive Heart Failure (CHF)
• 6.3 Renal, Obstetrics & Gynaecology
• 6.4 Oncology
• 6.5 Inflammatory Bowel Disease
• 6.6 Other Therapy Areas

7 Global Iron Deficiency Anemia (IDA) Therapy Market, By Age

• 7.1 Introduction
• 7.2 Geriatric
• 7.3 Adults
• 7.4 Pediatric

8 Global Iron Deficiency Anemia (IDA) Therapy Market, By End User

• 8.1 Introduction
• 8.2 Clinics
• 8.3 Hospitals
• 8.4 Home Healthcare

9 Global Iron Deficiency Anemia (IDA) Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Vifor Pharma Ltd
• 11.2 Teva Pharmaceutical Industries Ltd
• 11.3 Sanofi
• 11.4 Pfizer Inc
• 11.5 Novartis AG
• 11.6 Mylan N.V.
• 11.7 Lupin
• 11.8 Zydus Cadila
• 11.9 GlaxoSmithKline plc
• 11.10 Fresenius SE & Co. KGaA
• 11.11 F. Hoffmann-La Roche Ltd
• 11.12 Shield Therapeutics
• 11.13 Pharmacosmos A/S
• 11.14 AMAG Pharmaceuticals
• 11.15 Akebia Therapeutics, Inc
• 11.16 AbbVie Inc.
• 11.17 Hikma Pharmaceuticals plc
• 11.18 Alkem Laboratiories
• 11.19 Advanz Pharmaceutical
• 11.20 Rockwell Medical, Inc